CDKN2B and chronic myelogenous leukemia, BCR-ABL1 positive: In hematological malignancies p16INK4a and p15INK4b are frequently deleted e.g. in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) (66–70).